FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Clinical Trial ID NCT01413022

Rank	Title	Journal	Year	PubWeight™‹?›
1	Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.	Clin Cancer Res	2013	1.67
2	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.	Lancet Oncol	2016	1.61
3	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
4	Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.	J Hematol Oncol	2015	0.91
5	Targeting tumor-infiltrating macrophages to combat cancer.	Immunotherapy	2013	0.91
6	Metastatic pancreatic cancer: Is there a light at the end of the tunnel?	World J Gastroenterol	2015	0.87
7	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.	Oncoimmunology	2016	0.84
8	Macrophages and pancreatic ductal adenocarcinoma.	Cancer Lett	2015	0.77
9	Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages.	Oncoimmunology	2014	0.75
10	Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.	Curr Oncol	2012	0.75